Current Atherosclerosis Reports

Article	Citations
Revascularization Options for Left Main Disease: What Clinicians Need to Know	130
Are Clinicians Aggressive Enough in Treating Diabetes-Related Hyperlipidemia in Youth?	77
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions	76
Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?	76
Polysocial Risk Scores: Implications for Cardiovascular Disease Risk Assessment and Management	66
The Greatly Under-Represented Role of Smooth Muscle Cells in Atherosclerosis	60
A Narrative Review of the Association Between Depression and Heart Disease Among Women: Prevalence, Mechanisms of Action, and Treatment	59
Heart Transplant, Kawasaki Disease, and Bone Marrow Transplant: Are There Consequences?	53
PCSK9 Inhibition and Risk of Diabetes: Should We Worry?	52
Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management	51
The Effects of FABP4 on Cardiovascular Disease in the Aging Population	50
Ambient Air Pollution and Atherosclerosis: Recent Updates	48
Watermelon and l-Citrulline in Cardio-Metabolic Health: Review of the Evidence 2000–2020	47
From ‘Omics to Multi-omics Technologies: the Discovery of Novel Causal Mediators	47
Myocardial Infarction in the Absence of Obstructive Coronary Artery Disease (MINOCA): a Review of the Present and Preview of the Future	46
Polypharmacy and Cardiovascular Diseases: Consideration for Older Adults and Women	44
Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond	40
Genetic Testing for Familial Hypercholesterolemia in Clinical Practice	39
DOACs and Atherosclerotic Cardiovascular Disease Management: Can We Find the Right Balance Between Efficacy and Harm	38
The Genetic Basis of Hypertriglyceridemia	37
Programmable Genome-Editing Technologies as Single-Course Therapeutics for Atherosclerotic Cardiovascular Disease	36
Inflammation in the Peri-ACS Period: Ready for Prime Time?	34
The Emerging Specialty of Cardio-Rheumatology	34
Percutaneous Coronary Interventions in Women	33
Correction to: Beta‑blockers for Atherosclerosis Prevention: a Missed Opportunity?	32

Lipid Lowering Therapy Utilization and Lipid Goal Attainment in Women	30
The Role of Non-Statin Lipid Lowering Therapies to Reduce ASCVD Events in Primary Prevention	30
Nutrition Interventions for Youth with Dyslipidemia: Who, What, When, and Where?	30
Lipoprotein(a): from Causality to Treatment	29
The Intersection Between COVID-19, Cardiovascular Disease, and Diet: a Review	29
RNA Silencing in the Management of Dyslipidemias	29
Myeloid Cells in Abdominal Aortic Aneurysm	29
GLP-1 Receptor Agonists and Cardiovascular Disease: What Do Clinicians Need to Know?	29
The Role of Sleep in Cardiovascular Disease	28
Is There a Role of Coronary CTA in Primary Prevention? Current State and Future Directions	28
Implications of the Landmark ISCHEMIA Trial on the Initial Management of High-Risk Patients with Stable Ischemic Heart Disease	28
Hypertension in Women Across the Lifespan	28
Role of RNA-binding Proteins in Regulating Cell Adhesion and Progression of the Atherosclerotic Plaque and Plaque Erosion	27
Transgender Cardiovascular Health: Practical Management for the Clinician	27
Low LDL-C: Is It all Good News?	25
The Role of Bacterial Extracellular Membrane Nanovesicles in Atherosclerosis: Unraveling a Potential Trigger	25
Coronary Microvascular Dysfunction: What Clinicians and Investigators Should Know	24
Novel Therapies for Lipoprotein(a): Update in Cardiovascular Risk Estimation and Treatment	24
Childhood Hypertriglyceridemia: Is It Time for a New Approach?	24
Update on Plant-Based Diets and Cardiometabolic Risk	24
Importance of Nutrition Security to CVD Prevention Efforts in the USA	24
Effects of Omega-3 Fatty Acids on Flow-mediated Dilatation and Carotid Intima Media Thickness: A Meta-analysis	23
Correction to: High-Density Lipoproteins and Serum Amyloid A (SAA)	22
Stress, Vascular Smooth Muscle Cell Phenotype and Atherosclerosis: Novel Insight into Smooth Muscle Cell Phenotypic Transition in Atherosclerosis	22
In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show?	22
Implementing Reporting Standards for Polygenic Risk Scores for Atherosclerotic Cardiovascular Disease	22
Recent Advances in Stent Technology: Do They Reduce Cardiovascular Events?	21
Do Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD?	20
Dairy Foods: Is Its Cardiovascular Risk Profile Changing?	20
Is Family History for the Management of Cardiovascular Health in Youth Still Relevant in Clinical Practice?	20
Evidence Gaps in Assessments of the Healthiness of Online Supermarkets Highlight the Need for New Monitoring Tools: a Systematic Review	20
Eliminating Health Disparities in Atrial Fibrillation, Heart Failure, and Dyslipidemia: A Path Toward Achieving Pharmacoequity	19
Lipoprotein (a): Recent Updates on a Unique Lipoprotein	19
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American College of Cardiology Conference	19
SR-B1’s Next Top Model: Structural Perspectives on the Functions of the HDL Receptor	19
Noninvasive Atherosclerotic Phenotyping: The Next Frontier into Understanding the Pathobiology of Coronary Artery Disease	19
Membrane Cholesterol Interactions with Proteins in Hypercholesterolemia-Induced Endothelial Dysfunction	19
Brief Review: Racial and Ethnic Disparities in Cardiovascular Care with a Focus on Congenital Heart Disease and Precision Medicine	18
Gene Regulatory Networks in Coronary Artery Disease	18
Wall Shear Stress Alteration: a Local Risk Factor of Atherosclerosis	18
Major Concepts in Treatment with Bempedoic Acid and Inclisiran that Clinicians Need To Know	18
Is There a Role for Imaging Youth at Risk of Atherosclerosis?	18
Cardiovascular Health and Disease in the Pakistani American Population	17
Pharmacotherapy for Coronary Artery Disease and Acute Coronary Syndrome in the Aging Population	17
Inclisiran, Reasons for a Novel Agent in a Crowded Therapeutic Field	16
Targeting the Gut Microbiome to Treat Cardiometabolic Disease	16
Natural Sirtuin1 Activators and Atherosclerosis: an Overview	16
Bempedoic Acid: for Whom and When	16
What Causes Premature Coronary Artery Disease?	16
Extra-coronary Calcification and Cardiovascular Events: What Do We Know and Where Are We Heading?	15

Utility of FFRCT in Patients with Chest Pain	15
Biology, Bias, or Both? The Contribution of Sex and Gender to the Disparity in Cardiovascular Outcomes Between Women and Men	15
Managing of Dyslipidaemia Characterized by Accumulation of Triglyceride-Rich Lipoproteins	15
Long-Term Cardiovascular Effects of COVID-19: Emerging Data Relevant to the Cardiovascular Clinician	15
Non-obstructive Plaque and Treatment of INOCA: More to Be Learned	15
Statin Use in Special Populations for the Prevention of Cardiovascular Disease in Adults	15
Fixed Combination for the Treatment of Dyslipidaemia	14
Apheresis: What Should a Clinician Know?	14
A Review of Statin Intolerance: a Focus on Statin-Attributed Muscle Symptoms	14
Pregnancy Complications and Long-Term Atherosclerotic Cardiovascular Disease Risk	14
Anti-Inflammatory Lipid Mediators from Polyunsaturated Fatty Acids: Insights into their Role in Atherosclerosis Microenvironments	14
Combined Dyslipidemia in Children and Adolescents: a Proposed New Management Approach	14
Controversies in the Use of Omega-3 Fatty Acids to Prevent Atherosclerosis	14
Management of Hypercholesterolemia in Pregnant Women with Atherosclerotic Cardiovascular Disease	14
Managing Dyslipidemia in Chronic Kidney Disease: Implications for Cardiovascular and Renal Risk	14
Lipids: a Potential Molecular Pathway Towards Diastolic Dysfunction in Youth-Onset Type 2 Diabetes	13
Diet, Food Insecurity, and CVD Risk in Sexual and Gender Minority Adults	13
Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention	12
Psoriasis and Cardiovascular Disease: Novel Mechanisms and Evolving Therapeutics	12
Statins and Inflammation	12
Unraveling the miRNA Puzzle in Atherosclerosis: Revolutionizing Diagnosis, Prognosis, and Therapeutic Approaches	11
HDL as a Treatment Target: Should We Abandon This Idea?	11
Obicetrapib—the Rebirth of CETP Inhibitors?	11
Glycated Hemoglobin as an Integrator of Cardiovascular Risk in Individuals Without Diabetes: Lessons from Recent Epidemiologic Studies	11
The Effect of GLP-1 Receptor Agonists on Postprandial Lipaemia	11
European Lipid Guidelines and Cardiovascular Risk Estimation: Current Status and Future Challenges	11
Inhibition of Angiopoietin-Like Protein 3 or 3/8 Complex and ApoC-III in Severe Hypertriglyceridemia	11
LDL-C: The Only Causal Risk Factor for ASCVD. Why Is It Still Overlooked and Underestimated?	11
Managing Ischemic Heart Disease in Women: Role of a Women’s Heart Center	11
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 American Heart Association Scientific Sessions	11
Imaging Approaches to the Diagnosis of Vascular Diseases	11
Psychological Health and Ischemic Heart Disease in Women: A Review of Current Evidence and Clinical Considerations across the Healthspan	10
Cardiovascular Disease Burden among African Migrants	10
Can Digital Health Solutions Fill in the Gap for Effective Guideline Implementation in Cardiovascular Disease Prevention: Hope or Hype?	10
Targeting Inflammatory Pathways in Atherosclerosis: Exploring New Opportunities for Treatment	10
The TICE Pathway: Mechanisms and Potential Clinical Applications	10
Should Familial Hypercholesterolaemia Be Included in the UK Newborn Whole Genome Sequencing Programme?	10
The Atherosclerotic Plaque Microenvironment as a Therapeutic Target	10
Recent Advances in Coronary Computed Tomography Angiogram: The Ultimate Tool for Coronary Artery Disease	10
Coronary and Extra-coronary Subclinical Atherosclerosis to Guide Lipid-Lowering Therapy	10
How to Handle Elevated Triglycerides: Life after PROMINENT	9
An Update on Nutrition Guidance for Cardiovascular Health	9
Familial Hypercholesterolemia and Lipoprotein(a): Two Partners in Crime?	9
Statin Use and Hyperglycemia: Do Statins Cause Diabetes?	9
Dietary Influences on Atherosclerotic Cardiovascular Disease Risk	9
Cholesterol Lowering in Older Adults: Should We Wait for Further Evidence?	9
CETP Inhibitors: Should We Continue to Pursue This Pathway?	9
Advances, Challenges, and Progress in Cardiac Rehabilitation in Chronic CVD Management	9
Highlights from Studies Presented at the Virtual American College of Cardiology Scientific Sessions 2021: Staying Updated with the Latest Advancements in Prevention	9
Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors	8
Heart Failure Treatment in 2023: Is There a Place for Lipid Lowering Therapy?	8
Transitioning to GLP-1 RAs and SGLT2 Inhibitors as the First Choice for Managing Cardiometabolic Risk in Type 2 Diabetes	8
More than Just a Monolayer: the Multifaceted Role of Endothelial Cells in the Pathophysiology of Atherosclerosis	8
Correction to: Recent Advances in Stent Technology: Do They Reduce Cardiovascular Events?	8
Can We Mitigate Coronary Heart Disease Risk in Patients with Cancer?	8
Gene Editing for the Treatment of Hypercholesterolemia	8
Family Meals and Cardiometabolic Risk Factors in Young Children	8
Body Fat Depletion: the Yin Paradigm for Treating Type 2 Diabetes	8
Myocardial Bridge and Atherosclerosis, an Intimal Relationship	8
Achieving More Optimal Lipid Control with Non-Statin Lipid Lowering Therapy	8
Do Statins Affect Cognitive Health? A Narrative Review and Critical Analysis of the Evidence	8
LDL Transcytosis by the Arterial Endothelium—Atherosclerosis by a Thousand Cuts?	8
Mechanisms Behind NAFLD: a System Genetics Perspective	8
Update on Sitosterolemia and Atherosclerosis	8
Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?	8
Transitioning Adolescents and Young Adults with Lipid Disorders to Adult Health Care	7
Correction to: Built Environment and Cardiovascular Diseases – Insights from a Global Review	7
“Anti-inflammatory Therapies in Atherosclerosis – Where are we going?”	7
Biomarkers Differentiating Plaque Erosion from Stable Plaque	7
Inclisiran: How Widely and When Should We Use It?	7
The Role of Non-statin Lipid-Lowering Medications in Youth with Hypercholesterolemia	7
Sport as Medicine for Dyslipidemia (and Other Risk Factors)	7
Correction to: Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?	7
The Role of Coronary Artery Calcium Testing for Value-Based Clinical Trials in Primary Prevention	7
ADAMTS7: a Novel Therapeutic Target in Atherosclerosis	7
Lipoprotein Apheresis: Current Recommendations for Treating Familial Hypercholesterolemia and Elevated Lipoprotein(a)	7
Health Literacy is Essential to ASCVD Prevention in Youth	7
Eggs and Cardiovascular Disease Risk: An Update of Recent Evidence	7
The Management of Hypercholesterolemia in Patients with Neuromuscular Disorder	7
Coronary Microvascular Dysfunction: A Practical Approach to Diagnosis and Management	7

Familial Combined Hyperlipidemia: Myth or Reality?	7
Mechanosensing and Mechanosignal Transduction in Atherosclerosis	6
Effects of the COVID-19 Pandemic on Pediatric and Adolescent ASCVD Risk Factors	6
Double-Trouble: Atherosclerotic Risk Factors and Congenital Heart Disease	6
The Role of Cardiac PET in Diagnosis and Prognosis of Ischemic Heart Disease: Optimal Modality Across Different Patient Populations	6
The Role of Genetics in Advancing Cardiometabolic Drug Development	6
Invasive Coronary Assessment in Myocardial Ischemia with No Obstructive Coronary Arteries	6
Lipid Phenotypes and DNA Methylation: a Review of the Literature	6
Impact of Sex Differences on Lipids and Statin Utilization	6
Insight into the Mechanistic role of Colchicine in Atherosclerosis	6
ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future	6
Predictive Modeling and Structure Analysis of Genetic Variants in Familial Hypercholesterolemia: Implications for Diagnosis and Protein Interaction Studies	6
Impact of Selective Peroxisome Proliferator-Activated Receptor (PPAR)-α Modulators and Fibrates on Microvascular Disease: Is There Still Room?	6
Sex-based Differences in Complications Following Percutaneous Coronary Interventions	6
Medical and Surgical Obesity Treatments and Atherosclerosis: Mechanisms beyond Typical Risk Factors	6
Built Environment and Cardiovascular Diseases – Insights from a Global Review	6
Rap1 in the Context of PCSK9, Atherosclerosis, and Diabetes	6
PCSK9 and Coronary Artery Plaque—New Opportunity or Red Herring?	6
Protective Effects of Different Classes, Intensity, Cumulative Dose-Dependent of Statins Against Primary Ischemic Stroke in Patients with Type 2 Diabetes Mellitus	6
Updates in Small Interfering RNA for the Treatment of Dyslipidemias	6
Statin Intolerance: an Overview of US and International Guidance	6
Alcohol Consumption and Cardiovascular Disease Risk: Placing New Data in Context	6
Prevention of Atherosclerotic Cardiovascular Disease in Children with Familial Hypercholesterolemia	5
The Pandemic of Coronary Heart Disease in the Middle East and North Africa: What Clinicians Need to Know	5
Lp(a): A Rapidly Evolving Therapeutic Landscape	5
Evolution of Coronary Calcium Screening for Assessment of Atherosclerotic Cardiovascular Disease Risk and Role in Preventive Cardiology	5
Medication Induced Dyslipidemia in Children	5
Novel Therapeutics for Familial Chylomicronemia Syndrome	5
Telomere Length: Implications for Atherogenesis	5
Social Media and Cardiovascular Health: Implications for Women	5
Impact of Climate Change on Cardiovascular Health	5
Free Cholesterol Bioavailability and Atherosclerosis	5
SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?	5
Takotsubo Syndrome: Uncovering Myths and Misconceptions	5
Updates in Drug Treatment of Severe Hypertriglyceridemia	5
Medical Nutrition Therapy Provided by Dietitians is Effective and Saves Healthcare Costs in the Management of Adults with Dyslipidemia	5
Saturated Fat and Cardiovascular Health: Phenotype and Dietary Factors Influencing Interindividual Responsiveness	5